Half-year pre-tax profits at Wilmington Group fell to 3.7m pounds from 5.1m as its legal education business and healthcare divisions continued to face tough conditions.
The information provider also said Chief Executive Officer Charles Brady had decided to retire but would stay until a successor was in place.
Despite the profits fall, the company said its banking and compliance and pension and insurance information divisions were "enjoying strong organic growth" and that it planned to reinstate its progressive dividend policy.
It added that cash flow was strong going into the second half, and would fund further investment, a growing dividend and debt reduction.
Group revenues for the period increased rose 5% to £43.1m. Adjusted earnings before interest, tax and amortisation (EBITA) were up 15% to £8.2m and the adjusted EBITA margin improved to 19% from 2012's 17.4%. Adjusted earnings per share were up 14% at 6.2p.
Chairman Mark Asplin said the legal unit, which offers services such as expert witness training, had a tough end to its continuing professional development (CPD) course year and continued to face "challenging market conditions".
"There have also been strong competitive pressures in our Healthcare division but our prognosis for the medium term is encouraging with new products and potentially new markets opening up for us," Asplin said.
"Wilmington has had a good start to 2014. Recent acquisitions have been integrated and are contributing to group performance."
Asplin said Wilmington's overall trading environment had not changed significantly since its 2013 results announcement.
"Wilmington is a well-balanced business which is increasingly international and, as we move into the second half, our financial performance is on track to support our current expectations for the full year."
The interim dividend increased to 3.6p from 3.5p.
Veterinary drug group Dechra Pharmaceuticals boosted half-year revenue in most of its markets but a disappointing performance in the Netherlands, the phasing of export orders and US supply issues hit trading.
Dechra, which makes or markets products such as cat sedative Alfaxan and dog endocrinology treatment Forthyron, said underlying operating profit in the six months to December 31st rose 14.1% to £22.3m.
But revenue fell 0.7% to £95.9m, which Dechra blamed partly on the impact of new dispensing guidelines in the Netherlands.
It also attributed the drop to the timing of export orders and to problems with supplies of its Animax and sterile ophthalmic products in its US business.
After disposing of its services business last August, Dechra is focusing on selling existing products and maximising returns from those, expanding geographically to cash in on growth potential in Europe and emerging markets, and strategic acquisitions.
The group, which also said it was successfully integrating its Eurovet Animal Health acquisition into the business, declared an interim dividend of 4.75p per share, up 9.4% versus a year ago.
Dechra is facing pressure in Europe to reduce anti-microbial usage in animal medicine due to concerns of potential cross-over resistance from animals to humans by over-utilisation of antibiotics.
Chief Executive Ian Page said the company was confident that its earnings will meet its expectations for the financial year.
"We are, however, cautious regarding the overall economic environment and the ongoing concerns regarding antimicrobial products used in veterinary medicine," he said.